US 12,448,464 B2
Anti-PAD4 antibody
Mamoru Sato, Yokohama (JP); Michiyuki Yamada, Yokohama (JP); Satoshi Kanazawa, Nagoya (JP); Masayoshi Toyoura, Kyoto (JP); Yuji Shoya, Kyoto (JP); Kenji Saito, Kyoto (JP); and Chihiro Yamazaki, Kyoto (JP)
Assigned to PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, Yokohama (JP); PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY, Nagoya (JP); and PHARMA FOODS INTERNATIONAL CO., LTD., Kyoto (JP)
Filed by PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, Yokohama (JP); PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY, Nagoya (JP); and PHARMA FOODS INTERNATIONAL CO., LTD., Kyoto (JP)
Filed on Sep. 19, 2022, as Appl. No. 17/933,229.
Application 17/933,229 is a continuation of application No. 15/555,808, granted, now 11,447,569, previously published as PCT/JP2016/057030, filed on Mar. 7, 2016.
Claims priority of application No. 2015-044518 (JP), filed on Mar. 6, 2015.
Prior Publication US 2023/0192890 A1, Jun. 22, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); C07K 16/40 (2006.01); C12N 9/99 (2006.01); C12N 15/09 (2006.01); C12N 15/63 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/40 (2013.01) [A61K 39/395 (2013.01); A61K 39/3955 (2013.01); C12N 9/99 (2013.01); C12N 15/09 (2013.01); C12N 15/63 (2013.01); C12Y 305/03015 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 16 Claims
 
1. A method of treating rheumatoid arthritis (RA) or arthritis comprising administering to a patient in need thereof an anti-PAD4 (peptidylarginine deiminase 4) antibody in combination with a TNFα inhibitor, wherein the antibody specifically binds to positions 345, 347, and 348 of human PAD4.